Cross-sectional study of innate and acquired immunity in gut-associated lymphoid tissue ("GALT") in patients who have recovered from COVID-19

Cross-sectional study of innate and acquired immunity in gut-associated lymphoid tissue ("GALT") in patients who have recovered from COVID-19 - 2Long4COVID GALT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00027443

Enrollment

Registered

2022-06-24

Start date

2022-05-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Covid 19 state U09.9

Interventions

Group 1: As part of a medically indicated screening colonoscopy, samples are taken from the mucosa as well as blood samples.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - confirmed infection with SARS-CoV-2 three months before colonoscopy - Age at least 18 years - Presence of a consent form - Stable clinical health condition

Exclusion criteria

Exclusion criteria: - No existence of a declaration of consent - Age under 18 years -Presence of a chronic intestinal disease

Design outcomes

Primary

Measure	Time frame
Investigation of SARS-CoV- 2 persistence in GALT; evaluation of innate and adaptive immunity in GALT of patients with PCS.	—

Countries

Austria, Germany

Contacts

Public ContactClara Lehmann

Klinik I für Innere MedizinUniversitätsklinikum Köln (AöR)

clara.lehmann@uk-koeln.de+49 221 478 38374

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026